Abzena Ltd.

Abzena Ltd. is a contract development and manufacturing organization (CDMO) and contract research organization (CRO) specializing in complex biologics and bioconjugates, enabling biopharmaceutical companies to develop innovative therapies. Founded in 2001 and headquartered in Cambridge, UK, Abzena Ltd. provides integrated services for drug development and manufacturing.

The company has undergone strategic shifts, including being acquired by Welsh, Carson, Anderson & Stowe in October 2018, after raising GBP 20 million in both an IPO and a private placement in 2014 and 2015 respectively. Currently led by CEO Matthew Stober, Abzena has completed a total of 11 deals with its most recent funding round being a Secondary Buyout amounting to USD 10. 00 mn, raising the total amount raised to USD 10. 00 mn.

Abzena specializes in providing fully integrated CDMO and CRO services with a focus on complex biologics and bioconjugates, particularly antibody-drug conjugates (ADCs) and related products. Their services span the entire drug development process, ensuring high-quality data and tailored regulatory support for biopharmaceutical companies. In the most recent fiscal year 2023, Abzena reported revenue of USD 28. 95 mn and an EBITDA of USD 4.

43 mn, generated through contractual partnerships and service agreements within the biopharmaceutical sector. Abzena aims to expand its product offerings, launching new developments in bioconjugates aimed for release in the coming year. The company is targeting growth in North America and Asia by leveraging recent funding from the Secondary Buyout for enhancing operational capabilities and market reach, which aligns with its strategic vision for growth as outlined in its previous funding rounds.